Dyslipidaemia: Recommendations on the Role of PCSK9 Inhibitors in Lipids Management

Kausik K. Ray, MPhil, MD, BSc, MBChB


November 15, 2019

Statin therapy has been the mainstay of dyslipidaemia treatment for decades, but studies show that it is not effective for reaching recommended low-density lipoprotein (LDL) targets in all patients. Updated guidelines now call for even lower cholesterol targets in most risk categories, and new evidence suggests that PCSK9 inhibitors can play a role in lowering cholesterol to recommended levels.

Outcome studies show that not only do PCSK9 inhibitors have the potential to provide meaningful additional reductions in LDL levels, but they can also decrease the risk for cardiovascular events in high-risk patients.

Dr Kausik Ray, a cardiologist from Imperial College London, served as a member of the European Society of Cardiology/European Atherosclerosis Society Task Force, charged with advising physicians on appropriate use of PCSK9 inhibitors in cardiovascular patients. In this ReCAP, Dr Ray outlines the recommendations of that panel, providing up-to-date advice for using these therapies in clinical practice.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.